Ganetespib has shown preclinical activity against NSCLC models, including those driven by mutant EGFR, rearranged ALK, and/or mutant KRAS [4, 25, 26], and has been shown to potentiate the effect of taxanes and PI3K/mTOR inhibitor BEZ235 in NSCLC models [25, 26]. This evidence concerns the gene KRAS and non-small cell lung carcinoma.